| Literature DB >> 31459077 |
Mohd Shoeb1,1, Mohammad Mobin1, Mohd Ahmar Rauf2, Mohammad Owais2, Alim H Naqvi1.
Abstract
Nowadays, theEntities:
Year: 2018 PMID: 31459077 PMCID: PMC6645293 DOI: 10.1021/acsomega.8b00326
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1XRD spectrum of synthesized Gr1@PIn, Gr3@PIn, and PIn (inset: XRD shift).
Figure 2SEM images of (A) PIn, (B) Gr1@PIn, and (C) Gr3@PIn on the scale of 5 μm, respectively; (D) EDAX spectrum proves the elemental composition of as-synthesized Gr3@PIn (inset: presence of C, N, and O).
Figure 3HRTEM images of (A) PIn, (B) Gr1@PIn, and (C) Gr3@PIn, respectively; (A′) PIn, (B′) Gr1@PIn, and (C′) Gr3@PIn SAED pattern of the corresponding TEM images.
Figure 4FTIR spectra of the PIn, Gr1@PIn, and Gr3@PIn.
FTIR Functional Group Vibrations
| band (cm–1) | PIn | band (cm–1) | Gr@PIn (Gr1@PIn and Gr3@PIn) |
|---|---|---|---|
| 627 | –C–H (bending) | ||
| 744 | –C–H (bending) | 744 | –C–H (bending) |
| 1111 | –C–N (bending) | 1118 | –C–N (bending) |
| 1383 | –C=N (stretching) | 1375 | –C=N (stretching) |
| 1450 | –C–N (stretching) | 1455 | –C–N (stretching) |
| 1616 | –C=C (stretching) | 1604 | –C=C (stretching) |
| 3350 | –N–H (stretching) | 3350 | –N–H (stretching) |
Figure 5Raman spectrum of PIn, Gr1@PIn, and Gr3@PIn.
Figure 6UV–visible absorption spectra of PIn, Gr1@PIn, and Gr3@PIn.
Figure 7Graph of TGA-based thermal behavior of PIn, Gr1@PIn, and Gr3@PIn.
Figure 8Antibacterial activity of as-synthesized Gr@PIn formulations. (A) Zone of inhibition as a measure to establish the antibacterial potential of various Gr@PIn NC formulations against MRSA strains. (B) Fluorescence microscopic images showing MRSA ATCC BAA-1708 cells upon their treatment with various Gr@PIn formulations.
Agar Diffusion Assay for the Zone of Inhibition Observed (in mm units) against Result-Tested MRSA Strains
| strains | PIn | Gr1@PIn | Gr3@PIn | van (10 μg/disk) |
|---|---|---|---|---|
| ATCC 43300 | 5.667 ± 1.2 | 11.667 ± 2.082 | 20.667 ± 3.214 | 12.67 ± 2.309 |
| ATCC BAA-1708 | 5.33 ± 1.2 | 10.33 ± 2 | 17.667 ± 2.082 | 10.67 ± 2.5 |
Figure 9Antibiofilm activity of different Gr@PIn formulations (A). Effect of Gr@PIn nanocomposite against biofilm development in MRSA ATCC BAA-1708 strain. Growth inhibition was assessed by comparing relative metabolic activity determined using XTT assay; untreated control was considered showing 100% activities. Experiments were performed in triplicates; results are shown as mean ± standard deviation (SD); **P ≤ 0.01; ***P ≤ 0.001.
Figure 10In vitro CFU counts assay. CFU counts as residual MRSA ATCC BAA-1708 surviving after exposure to various forms of Gr@PIn nanocomposite.
Figure 11Electron microscopic observation of MRSA when coincubated with different Gr@PIn. (A) SEM micrograph depicting the interaction of various Gr3@PIn with MRSA ATCC BAA-1708 strain. B. TEM showing the interaction of various Gr3@PIn with MRSA ATCC BAA-1708 strain.
Figure 12Effect of varying concentrations of Gr@PIn nanocomposite on RBC leakage.
Figure 13Effect of Gr@PIn formulations on experimental skin infection (A); efficacy of Gr3@PIn against the examination of mice skin. (B) Mice were infected topically with MRSA ATCC BAA-1708 and treated with various Gr@PIn groups concurrently after infection. Mice inoculated with phosphate-buffered saline alone were used as a control. After treatment with various Gr@PIn, skin lesions were cut; the homogenized and bacterial count was determined by CFU assay on the 11th day; (C) on day 11, biopsy specimens were taken instantly after the conclusion of the experiment, fixed in 4% neutral-buffered formalin and embedded in parafilm. The biopsy specimens were stained with HE. Experiments were performed in triplicates; results are shown as mean ± SD; ***P ≤ 0.001.
Values of log10 CFU/mL in Tabular Form
| pathogen | groups | log10 CFU/mL |
|---|---|---|
| MRSA 43300 | positive control | 5.969 |
| PIn | 5.393 | |
| Gr1@PIn | 4.872 | |
| Gr3@PIn | 4.300 | |
| vancomycin | 4.170 |